Advertisement

The journal of nutrition, health & aging

, Volume 21, Issue 4, pp 449–456 | Cite as

Effectiveness of cardiac rehabilitation for prevention and treatment of sarcopenia in patients with cardiovascular disease - a retrospective cross-sectional analysis

  • H. Harada
  • H. Kai
  • H. Niiyama
  • Y. Nishiyama
  • A. Katoh
  • N. Yoshida
  • Y. Fukumoto
  • Hisao Ikeda
Article

Abstract

Objective

Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, with the risk of frailty and poor quality of life. This study aimed to clarify the clinical characteristics of sarcopenia and to investigate the effects of comprehensive cardiac rehabilitation (CCR), including nutrition, physical exercise and medication, in patients with cardiovascular disease (CVD).

Methods

We retrospectively studied 322 inpatients with CVD (age 72±12 years). Muscle mass, muscle strength and physical performance were assessed before and after exercise training in patients with and without sarcopenia, which was defined as either a gait speed of <0.8 m/s or reduced handgrip strength (<26 kg in males and <18 kg in females), together with lower skeletal muscle index (SMI) (<7.0 kg/m2 in males and <5.7 kg/m2 in females). The actual daily total calorie and nutrient intake was also calculated.

Results

Sarcopenia was identified in 28% of patients with CVD, these patients having a higher prevalence of symptomatic chronic heart failure and chronic kidney disease. SMI was significantly associated with protein intake and statin treatment. The ratio of peak VO2 and SMI was significantly higher in the statin treatment group. Handgrip strength, gait speed, leg weight bearing index, and nutritional intake improved after exercise training in patients both with and without sarcopenia.

Conclusions

The present findings suggest that CCR is a promising strategy for prevention and treatment of sarcopenia in patients with CVD.

Key words

Cardiac rehabilitation cardiovascular disease chronic heart failure sarcopenia statin 

References

  1. 1.
    Xue QL. The frailty syndrome: Definition and natural history. Clin Geriatr Med. 2011; 27: 1–15.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age and Ageing. 2010; 39: 412–423.Google Scholar
  3. 3.
    Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update A Guideline From the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458–2473.CrossRefPubMedGoogle Scholar
  4. 4.
    Hunt SA, Abraham WT, Chin MH, et al. Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: e391–e479, DOI: 10.1161/CIRCULATIONAHA.109.192065.CrossRefPubMedGoogle Scholar
  5. 5.
    Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005; 20: 38–45.Google Scholar
  6. 6.
    Kyle UG, Bosaeus I, de Lorenzo AD, et al. Bioelectrical impedance analysis—part II: utilization in clinical practice. Clinical Nutrition. 2004; 23: 1430–1453.CrossRefPubMedGoogle Scholar
  7. 7.
    Chang EJ, Jung HW, Kim SW, Heo NJ, Chin HJ, Kim CH, Kim KI. Determining the cut-off values for sarcopenia in the Korean elderly population using bioimpedance analysis. J Frailty Aging 2015; 4: 34–40.PubMedGoogle Scholar
  8. 8.
    Tanimoto Y, Watanabe M, Sun W, et al. Association between sarcopenia and higherlevel functional capacity in daily living in community-dwelling elderly subjects in Japan. Archives of Gerontology and Geriatrics. 2012; 55: e9–e13, doi: 10.1016/j.archger.2012.06.015. Epub 2012 Jul 12.CrossRefPubMedGoogle Scholar
  9. 9.
    Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014; 15: 95–101.CrossRefPubMedGoogle Scholar
  10. 10.
    Houston DK, Nicklas BJ, Ding J, et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study1–3. Am J Clin Nutr. 2008; 87: 150–155.PubMedGoogle Scholar
  11. 11.
    Miyatake N, Takanami S, Kawasaki Y, Fujii M. Relationship between visceral fat accumulation and physical fitness in Japanese women. Diabetes Research and Clinical Practice. 2004; 64: 173–179.CrossRefPubMedGoogle Scholar
  12. 12.
    Sale DG. Neural adaptation to resistance training. Med Sci Sports Exerc. 1988; 20: 135–145.CrossRefGoogle Scholar
  13. 13.
    Gabriel DA, Kamen G, Frost G. Neural adaptations to resistive exercise Mechanisms and recommendations for training practices. Sports Med. 2006; 36: 133–149.CrossRefPubMedGoogle Scholar
  14. 14.
    Alway SE, Myers MJ, Mohamed JS. Regulation of satellite cell function in sarcopenia. Frontiers in Aging Neuroscience. 2014; 6: 1–15, doi: 10.3389/fnagi.2014.00246.CrossRefGoogle Scholar
  15. 15.
    Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Medicine. 2000; 6: 1004–1010.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Dickinson JM, Fry CS, Drummond MJ, et al. Mammalian Target of Rapamycin Complex 1 Activation Is Required for the Stimulation of Human Skeletal Muscle Protein Synthesis by Essential Amino Acids. J Nutr. 2011; 141: 856–862.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Nakao T, Shiota M, Tatemoto Y, Izumi Y, Iwao H. Pravastatin Induces Rat Aortic Endothelial Cell Proliferation and Migration via Activation of PI3K/Akt/mTOR/p70 S6 Kinase Signaling. J Pharmacol Sci. 2007; 105: 334–341.CrossRefPubMedGoogle Scholar
  18. 18.
    Kou R, Sartoretto J, Michel T. Regulation of Rac1 by Simvastatin in Endothelial Cells Differential Roles of AMP-Activated Protein Kinase And Calmodulin-Dependent Kinase Kinase-ß. J Biol Chem. 2009; 284: 14734–14743.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hermida N, Markl A, Hamelet J, et al. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovascular Research. 2013; 99: 44–54.CrossRefPubMedGoogle Scholar
  20. 20.
    Memmott RM, Dennis PA. Akt-dependent and independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009; 21: 656–664.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Zhu K, Chen X, Liu J, Ye H, Zhu L, Wu JY. AMPK interacts with DSCAM and plays an important role in Netrin-1 induced neurite outgrowth. Protein Cell. 2013; 4: 155–161.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of Atorvastatin and Pravastatin on Signal Transduction Related to Glucose Uptake in 3T3L1 Adipocytes. J Pharmacol Sci. 2008; 107: 80–89.CrossRefPubMedGoogle Scholar
  23. 23.
    Nicholson AC, Hajjar DP, Zhou X, He W, Gotto AM, Han J. Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARc and Pref-1 expression. British Journal of Pharmacology. 2007; 151: 807–815.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Russ DW, Gregg-Cornell K, Conaway MJ, Clark BC. Evolving concepts on the agerelated changes in “muscle quality”. J Cachexia Sarcopenia Muscle. 2012; 3: 95–109.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fry CS, Drummond MJ, Glynn EL, et al. Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis. Skelet. Muscle. 2011; 1: 11–21. doi:10.1186/2044-5040-1-11.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Serra-Prat M, Papiol M, Monteis R, Palomera E, Cabré M. Relationship between Plasma Ghrelin Levels and Sarcopenia in Elderly Subjects: A Cross-Sectional Study. J Nutr Health Aging. 2015; 19: 669–72. doi: 10.1007/s12603-015-0550-8.CrossRefPubMedGoogle Scholar

Copyright information

© Serdi and Springer-Verlag France 2017

Authors and Affiliations

  • H. Harada
    • 1
  • H. Kai
    • 1
  • H. Niiyama
    • 1
  • Y. Nishiyama
    • 1
  • A. Katoh
    • 1
  • N. Yoshida
    • 2
  • Y. Fukumoto
    • 3
  • Hisao Ikeda
    • 4
  1. 1.Department of CardiologyKurume University Medical CenterKurumeJapan
  2. 2.Institute of Health and Sports SciencesKurume UniversityKurumeJapan
  3. 3.Department of Cardio-vascular MedicineKurume University School of MedicineKurumeJapan
  4. 4.Department of Physical Therapy, Faculty of Fukuoka Medical TechnologyTeikyo UniversityFukuokaJapan

Personalised recommendations